These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

336 related items for PubMed ID: 26774113

  • 1. Bevacizumab safety in Japanese patients with colorectal cancer.
    Hatake K, Doi T, Uetake H, Takahashi Y, Ishihara Y, Shirao K.
    Jpn J Clin Oncol; 2016 Mar; 46(3):234-40. PubMed ID: 26774113
    [Abstract] [Full Text] [Related]

  • 2. Retrospective cohort study on the safety and efficacy of bevacizumab with chemotherapy for metastatic colorectal cancer patients: the HGCSG0801 study.
    Sogabe S, Komatsu Y, Yuki S, Kusumi T, Hatanaka K, Nakamura M, Kato T, Miyagishima T, Hosokawa A, Iwanaga I, Sakata Y, Asaka M.
    Jpn J Clin Oncol; 2011 Apr; 41(4):490-7. PubMed ID: 21303790
    [Abstract] [Full Text] [Related]

  • 3. Bleeding after bevacizumab treatment in patients with metastatic colorectal cancer.
    Cao D, Guo CH, Liu JW, Yang X, Li Q.
    Tumori; 2015 Apr; 101(1):46-51. PubMed ID: 25702674
    [Abstract] [Full Text] [Related]

  • 4. The feasibility of a short bevacizumab infusion in patients with metastatic colorectal cancer.
    Terazawa T, Nishitani H, Kato K, Hashimoto H, Akiyoshi K, Iwasa S, Nakajima TE, Hamaguchi T, Yamada Y, Shimada Y.
    Anticancer Res; 2014 Feb; 34(2):1053-6. PubMed ID: 24511054
    [Abstract] [Full Text] [Related]

  • 5. FOLFOXIRI plus bevacizumab versus FOLFIRI plus bevacizumab as first-line treatment of patients with metastatic colorectal cancer: updated overall survival and molecular subgroup analyses of the open-label, phase 3 TRIBE study.
    Cremolini C, Loupakis F, Antoniotti C, Lupi C, Sensi E, Lonardi S, Mezi S, Tomasello G, Ronzoni M, Zaniboni A, Tonini G, Carlomagno C, Allegrini G, Chiara S, D'Amico M, Granetto C, Cazzaniga M, Boni L, Fontanini G, Falcone A.
    Lancet Oncol; 2015 Oct; 16(13):1306-15. PubMed ID: 26338525
    [Abstract] [Full Text] [Related]

  • 6. Managing patients treated with bevacizumab combination therapy.
    Gordon MS, Cunningham D.
    Oncology; 2005 Oct; 69 Suppl 3():25-33. PubMed ID: 16301833
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. A phase II study of bevacizumab with modified OPTIMOX1 as first-line therapy for metastatic colorectal cancer: the TCOG-GI 0802 study.
    Nakayama N, Sato A, Tanaka S, Shimada K, Konishi K, Sasaki E, Hibi K, Ichikawa H, Kikuchi Y, Sakuyama T, Sekikawa T, Hayashi K, Nishina H, Tokyo Cooperative Oncology Group, Tokyo, Japan.
    Invest New Drugs; 2015 Aug; 33(4):954-62. PubMed ID: 25937430
    [Abstract] [Full Text] [Related]

  • 10. Bevacizumab in the treatment of metastatic colorectal cancer: safety profile and management of adverse events.
    Hurwitz H, Saini S.
    Semin Oncol; 2006 Oct; 33(5 Suppl 10):S26-34. PubMed ID: 17145522
    [Abstract] [Full Text] [Related]

  • 11. Bevacizumab plus chemotherapy as first-line treatment for patients with metastatic colorectal cancer: results from a large German community-based observational cohort study.
    Stein A, Petersen V, Schulze M, Seraphin J, Hoeffkes HG, Valdix AR, Schroeder J, Herrenberger J, Boxberger F, Leutgeb B, Hinke A, Kutscheidt A, Arnold D.
    Acta Oncol; 2015 Feb; 54(2):171-8. PubMed ID: 25307517
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Effect of First-Line Chemotherapy Combined With Cetuximab or Bevacizumab on Overall Survival in Patients With KRAS Wild-Type Advanced or Metastatic Colorectal Cancer: A Randomized Clinical Trial.
    Venook AP, Niedzwiecki D, Lenz HJ, Innocenti F, Fruth B, Meyerhardt JA, Schrag D, Greene C, O'Neil BH, Atkins JN, Berry S, Polite BN, O'Reilly EM, Goldberg RM, Hochster HS, Schilsky RL, Bertagnolli MM, El-Khoueiry AB, Watson P, Benson AB, Mulkerin DL, Mayer RJ, Blanke C.
    JAMA; 2017 Jun 20; 317(23):2392-2401. PubMed ID: 28632865
    [Abstract] [Full Text] [Related]

  • 14. Bevacizumab with FOLFOXIRI (irinotecan, oxaliplatin, fluorouracil, and folinate) as first-line treatment for metastatic colorectal cancer: a phase 2 trial.
    Masi G, Loupakis F, Salvatore L, Fornaro L, Cremolini C, Cupini S, Ciarlo A, Del Monte F, Cortesi E, Amoroso D, Granetto C, Fontanini G, Sensi E, Lupi C, Andreuccetti M, Falcone A.
    Lancet Oncol; 2010 Sep 20; 11(9):845-52. PubMed ID: 20702138
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy and safety of an irinotecan plus bolus 5-fluorouracil and L-leucovorin regimen for metastatic colorectal cancer in Japanese patients: experience in a single institution in Japan.
    Yoshino T, Boku N, Onozawa Y, Hironaka S, Fukutomi A, Yamaguchi Y, Hasuike N, Yamazaki K, Machida N, Ono H.
    Jpn J Clin Oncol; 2007 Sep 20; 37(9):686-91. PubMed ID: 17720736
    [Abstract] [Full Text] [Related]

  • 18. [Evaluation of bevacizumab for advanced colorectal cancer].
    Naito M, Hoshino S, Noda N, Nakano M, Matsuo K, Yamauchi Y, Shinohara T, Tanaka S, Yamashita Y.
    Gan To Kagaku Ryoho; 2010 Jan 20; 37(1):83-8. PubMed ID: 20087037
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Bevacizumab plus irinotecan-based regimens in the treatment of metastatic colorectal cancer.
    Heinemann V, Hoff PM.
    Oncology; 2010 Jan 20; 79(1-2):118-28. PubMed ID: 21088438
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 17.